Survival rates with two approaches were similar, but one came with more complications ...

Dermata Therapeutics (DRMA) announced that additional analysis of topline data from its Phase 3 STAR-1 trial showed that XYNGARI had a statistically significant difference from placebo on three ...

Digital morphometric analysis of mixed odontogenic tumors identified significant differences in virtual epithelial cell architecture.

ICIs have transformed NSCLC treatment, but disparities in trial enrollment and efficacy reporting persist, limiting insights into treatment benefits across demographics. A meta-analysis of 21 trials ...

No significant differences in resistance were observed against participants with acne vulgaris (AV) against 7 antibiotics. Moreover, some resistances were seen against clindamycin, erythromycin, and ...